BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved
'Unequivocal Benefit' Unveiled At ESC
Executive Summary
The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.
You may also be interested in...
Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure
Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.
AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data
AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.
Boehringer Pharma Chief Confident Of Continued Success For Jardiance
Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.